Literature DB >> 21962096

Variations in expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in nasal mucosa of aspirin-sensitive versus aspirin-tolerant patients with nasal polyposis.

Pamela A Mudd1, Rohit K Katial, Raeful Alam, Samantha Hohensee, Vijay Ramakrishnan, Todd T Kingdom.   

Abstract

BACKGROUND: Matrix metalloproteinases (MMPs) are key enzymes responsible for extracellular matrix degradation contributing to the progressive histological changes seen in lower airway disease, including asthma. MMP-9 and TIMP-1 have also shown some role in the pathogenesis of chronic rhinosinusitis (CRS) and nasal polyposis (NP).
OBJECTIVE: We aim to determine variability in expression of MMP-9 and its inhibitor, tissue inhibitor of metalloproteinase-1 (TIMP-1), in sinus tissue from distinct patient populations presenting with nasal polyposis.
METHODS: The expression of MMP-9 and TIMP-1 was investigated in nasal polyp tissue from 6 aspirin-sensitive (AS) and 6 aspirin-tolerant (AT) patients undergoing endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis (CRSwNP). Sinus mucosa from 6 patients with chronic rhinosinusitis without nasal polyposis (CRSsNP) was used as control. The MMP-9 and TIMP-1 expression was measured using immunofluorescence technique and graded using manual and computerized methods.
RESULTS: Expression of TIMP-1 was significantly reduced in the AS group when compared with both the AT and CRSsNP (control) groups (P < .001). The MMP-9/TIMP-1 ratio was significantly increased in the AS group when compared with other patient groups (P < .001). The MMP- 9 expression was similar between study and control groups.
CONCLUSION: These results support the importance of MMP-9 and TIMP-1 expression in nasal polyp formation. The decreased expression of TIMP-1 in AS patients may promote the effects of MMP-9 expression and thus contribute to tissue remodeling and inflammatory changes. This finding may lead to further understanding of disease severity and resistance to treatment in this group of patients, as well as the pathogenesis of nasal polyps.
Copyright © 2011 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21962096      PMCID: PMC3370417          DOI: 10.1016/j.anai.2011.07.016

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  25 in total

1.  Oral steroids and doxycycline: two different approaches to treat nasal polyps.

Authors:  Thibaut Van Zele; Philippe Gevaert; Gabriele Holtappels; Achim Beule; Peter John Wormald; Susanne Mayr; Greet Hens; Peter Hellings; Fenna A Ebbens; Wytske Fokkens; Paul Van Cauwenberge; Claus Bachert
Journal:  J Allergy Clin Immunol       Date:  2010-05       Impact factor: 10.793

Review 2.  Aspirin intolerance and nasal polyposis.

Authors:  César Picado
Journal:  Curr Allergy Asthma Rep       Date:  2002-11       Impact factor: 4.806

3.  Increased matrix metalloproteinase-9 in the airway after allergen challenge.

Authors:  E A Kelly; W W Busse; N N Jarjour
Journal:  Am J Respir Crit Care Med       Date:  2000-09       Impact factor: 21.405

Review 4.  Matrix metalloproteinase-9 and airway remodeling in asthma.

Authors:  Hiroyuki Ohbayashi; Kaoru Shimokata
Journal:  Curr Drug Targets Inflamm Allergy       Date:  2005-04

5.  The role of MMP-9 and TIMP-1 in nasal polyp formation.

Authors:  Orban Kermal Kahveci; Fevzi Sefa Derekoy; Mustafa Yilmaz; Mustafa Serteser; Ali Altuntas
Journal:  Swiss Med Wkly       Date:  2008-11-15       Impact factor: 2.193

6.  Nonasthmatic nasal polyposis patients with allergy exhibit greater epithelial MMP positivity.

Authors:  Hyun-Woo Shin; Doo Hee Han; Yune Sung Lim; Hye Jung Kim; Dong-Young Kim; Chul Hee Lee; Yang-Gi Min; Chae-Seo Rhee
Journal:  Otolaryngol Head Neck Surg       Date:  2009-10       Impact factor: 3.497

7.  A matrix metalloproteinase inhibitor to treat unresectable cholangiocarcinoma.

Authors:  J J French; M J Midwinter; M K Bennett; D M Manas; R M Charnley
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

Review 8.  Management of aspirin-sensitive rhinosinusitis-asthma syndrome: what role for aspirin desensitization?

Authors:  M L Kowalski
Journal:  Allergy Proc       Date:  1992 Jul-Aug

Review 9.  Important research questions in allergy and related diseases: 3-chronic rhinosinusitis and nasal polyposis - a GALEN study.

Authors:  C Bachert; N Van Bruaene; E Toskala; N Zhang; H Olze; G Scadding; C M Van Drunen; J Mullol; L Cardell; P Gevaert; T Van Zele; S Claeys; C Halldén; K Kostamo; U Foerster; M Kowalski; K Bieniek; A Olszewska-Ziaber; E Nizankowska-Mogilnicka; A Szczeklik; M Swierczynska; M Arcimowicz; V Lund; W Fokkens; T Zuberbier; C Akdis; G Canonica; P Van Cauwenberge; P Burney; J Bousquet
Journal:  Allergy       Date:  2009-04       Impact factor: 13.146

10.  A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis.

Authors:  Ben Wallwork; William Coman; Alan Mackay-Sim; Lennart Greiff; Anders Cervin
Journal:  Laryngoscope       Date:  2006-02       Impact factor: 3.325

View more
  2 in total

1.  Involvement of the extracellular matrix proteins periostin and tenascin C in nasal polyp remodeling by regulating the expression of MMPs.

Authors:  Kun Du; Min Wang; Nan Zhang; Pei Yu; Ping Wang; Ying Li; Xiangdong Wang; Luo Zhang; Claus Bachert
Journal:  Clin Transl Allergy       Date:  2021-09-06       Impact factor: 5.657

2.  Downregulation of miR‑29b‑3p promotes α‑tubulin deacetylation by targeting the interaction of matrix metalloproteinase‑9 with integrin β1 in nasal polyps.

Authors:  Zhuohui Liu; Haoyu Liu; Deshun Yu; Jingyu Gao; Biao Ruan; Ruiqing Long
Journal:  Int J Mol Med       Date:  2021-05-13       Impact factor: 4.101

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.